Nanobiotix SA Aktie

6,02 EUR -0,08 EUR -1,31 %

07:30:10

BMN

6,05 EUR +0,36 EUR +6,33 %

29.07.2025

PAR

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.268,06 Mio. EUR

Div. Rendite0,00%

WKNA1J7EB

ISINFR0011341205

SymbolNNBXF

Nanobiotix SA Aktien News

Sortieren:Datum Meistgelesen

24.04.24GlobeNewswireNANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

17.04.24GlobeNewswireNANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024

10.04.24GlobeNewswireVoting Rights and Shares Capital of the Company

02.04.24GlobeNewswireNanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation

06.03.24GlobeNewswireNanobiotix to Present at Upcoming Investor Conferences in March

13.02.24GlobeNewswireVoting Rights and Shares Capital of the Company

31.01.24GlobeNewswireNanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

29.01.24GlobeNewswireNanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study

11.01.24GlobeNewswireVoting Rights and Shares Capital of the Company

26.12.23GlobeNewswireNanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets

13.12.23GlobeNewswireVoting Rights and Shares Capital of the Company

04.12.23GlobeNewswireNanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.

13.11.23GlobeNewswireNANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update

09.11.23GlobeNewswireNANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023

08.11.23GlobeNewswireVoting Rights and Shares Capital of the Company

07.11.23GlobeNewswireNANOBIOTIX Announces Closing of Global Offering

06.11.23GlobeNewswireNANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment

02.11.23GlobeNewswireNANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M

01.11.23GlobeNewswireNANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant

23.10.23GlobeNewswireNANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

11.10.23GlobeNewswireVoting Rights and Shares Capital of the Company

04.10.23GlobeNewswireNanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival o

29.09.23GlobeNewswireNANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation O

28.09.23GlobeNewswireNANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer

26.09.23GlobeNewswireNANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023

19.09.23GlobeNewswireNanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023

13.09.23GlobeNewswireVoting Rights and Shares Capital of the Company

05.09.23GlobeNewswireNANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer

31.08.23GlobeNewswireNANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference

15.08.23GlobeNewswireNANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

04.08.23GlobeNewswireNANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023

20.07.23GlobeNewswireVoting Rights and Shares Capital of the Company

19.07.23GlobeNewswireNANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

10.07.23GlobeNewswireNANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3

08.06.23GlobeNewswireVoting Rights and Shares Capital of the Company

17.05.23GlobeNewswireNANOBIOTIX Provides First Quarter 2023 Operational and Financial Update

05.05.23GlobeNewswireNANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company

25.04.23GlobeNewswireNANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results

17.04.23GlobeNewswireNANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023

11.04.23GlobeNewswireVoting Rights and Shares Capital of the Company

Nanobiotix SA News

Nanobiotix SA News: auf dieser Seite finden Sie alle Nanobiotix SA News und Nachrichten zur Nanobiotix SA Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Nanobiotix SA News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Nanobiotix SA News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.